News

There are convincing data supporting the concept that abnormalities in cortisol activity are an important cause of insulin resistance, visceral fat deposition, elevated cholesterol and blood pressure. These

The trial, which enrolled 103 patients in the US and Canada, studied the effect of a 12 week treatment of CRx-140 compared to low-dose cyclosporine. However, the drug

This study will evaluate the tolerability, safety, and pharmacokinetics of IMS in normal human volunteers. IMS represents Inotek’s the second compound to have entered clinical trials The company

A six-month priority review is a significant acceleration of the standard review process for new drugs which takes ten months. Priority review is granted to drugs that, if

Although no intravenous formulation has ever been available in the US, other formulations of acetaminophen have been available for over 50 years. IV APAP has, however, been marketed

The companies now plan to progress the development of the compounds into the next phase, focused on compound optimization and advancement of the program towards development. Under the

Anturol, which utilizes Antares’ proprietary advanced transdermal delivery (ATD) gel platform, is expected to begin pivotal phase III clinical trials during the second half of 2006. Oxybutynin, the

Axcan said that it will decide on whether or not to continue developing the drug in its functional dyspepsia indication after it has further evaluated data from the

This designation will provide a 10-year period of market exclusivity if AS1411 is approved as a treatment for either disease. The drug already has US orphan drug status